Identification

Name
Pirenzepine
Accession Number
DB00670  (APRD00515)
Type
Small Molecule
Groups
Approved
Description

An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. It is generally well tolerated by patients. [PubChem]

Structure
Thumb
Synonyms
  • 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one
  • Pirenzepin
  • Pirenzepina
  • Pirenzépine
  • Pirenzepinum
External IDs
ACI-91 / L-S519
Product Ingredients
IngredientUNIICASInChI Key
Pirenzepine Hydrochloride10YM403FLS 29868-97-1FFNMBRCFFADNAO-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gastrozepin Tab 50mgTablet50 mgOralBoehringer Ingelheim (Canada) Ltd Ltee1984-12-311996-09-09Canada
International/Other Brands
Anquwei (Panion & BF) / Folinzepin (Tsuruhara Seiyaku) / Garendopine (Choseido Pharmaceutical) / Gaspin (Gentle) / Gastrozepin (Boehringer Ingelheim) / Gastsion (Shiono Kemikaru) / Gaszepin (Swiss Pharm) / Karoderin (Nippon Chemiphar) / Kawaipin (Siu Guan) / Kiccalzin (Takata Seiyaku) / Lizepine (Health Chemical) / Lonzepin (Li Ta) / Muszepin (Royal) / Pilenzel (Taiyo Pharmaceutical) / Pin (Tatsumi Kagaku) / Pirepine (Yu Sheng) / Pirodeine (Medisa Shinyaku) / Pizepine (Yuan Chou) / Ranclic (Towa Yakuhin) / Regastric (Jinup) / Stomazepin (Taisho Yakuhin) / Ulopine (Panbiotic)
Categories
UNII
3G0285N20N
CAS number
28797-61-7
Weight
Average: 351.4023
Monoisotopic: 351.169524941
Chemical Formula
C19H21N5O2
InChI Key
RMHMFHUVIITRHF-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)
IUPAC Name
2-[2-(4-methylpiperazin-1-yl)acetyl]-2,4,9-triazatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one
SMILES
CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1

Pharmacology

Indication

For the treatment of peptic ulcer, gastric ulcer, and duodenal ulcer.

Structured Indications
Not Available
Pharmacodynamics

Pirenzepine belongs to a group of medications called antispasmodics/anticholinergics. These medications are used to relieve cramps or spasms of the stomach, intestines, and bladder. Pirenzepine is used to treat duodenal or stomach ulcers or intestine problems. It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.

Mechanism of action

Pirenzepine is a muscarinic receptor antagonist and binds to the muscarinic acetylcholine receptor. The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Pirenzepine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Pirenzepine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Ambenonium.Approved
Ambroxol acefyllinateThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Ambroxol acefyllinate.Experimental
AminophyllineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Aminophylline.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pirenzepine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Atracurium.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pirenzepine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pirenzepine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pirenzepine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pirenzepine.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Pirenzepine.Experimental
Botulinum Toxin Type APirenzepine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BPirenzepine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Pirenzepine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Pirenzepine.Approved
CimetropiumPirenzepine may increase the anticholinergic activities of Cimetropium.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Pirenzepine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pirenzepine.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pirenzepine.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pirenzepine.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dicyclomine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Pirenzepine is combined with DPDPE.Investigational
DronabinolPirenzepine may increase the tachycardic activities of Dronabinol.Approved, Illicit
DyphyllineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Dyphylline.Approved
EchothiophateThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Edrophonium.Approved
EluxadolinePirenzepine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Emepronium.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pirenzepine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Fesoterodine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Pirenzepine.Approved
GalantamineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pirenzepine.Approved
Ginkgo bilobaThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Glucagon recombinant.Approved
GlycopyrroniumPirenzepine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pirenzepine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pirenzepine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pirenzepine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Pirenzepine.Approved
IpidacrineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pirenzepine.Approved
IsoflurophateThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Pirenzepine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pirenzepine.Approved
MefloquineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Meptazinol.Experimental
MethadonePirenzepine may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Methantheline.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Pirenzepine.Approved
Methyl salicylateThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MetixeneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Pirenzepine.Approved
MianserinMianserin may increase the anticholinergic activities of Pirenzepine.Approved
MinaprineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Morphine.Approved, Investigational
NabilonePirenzepine may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Normethadone.Approved, Illicit
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pirenzepine.Approved, Investigational
OpiumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pirenzepine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Otilonium.Experimental
OxitropiumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pirenzepine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pancuronium.Approved
ParaoxonThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Pirenzepine.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Phenoperidine.Experimental
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Pirenzepine.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pipecuronium.Approved
PiritramideThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Pirenzepine.Approved
Potassium ChloridePirenzepine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Pirenzepine.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pirenzepine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Propiverine.Investigational
PyridostigmineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Pirenzepine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Quinidine.Approved
RamosetronPirenzepine may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pirenzepine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Pirenzepine.Approved, Investigational
Sodium oxybatePirenzepine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Solifenacin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pirenzepine.Approved
TacrineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tapentadol.Approved
TeduglutideThe serum concentration of Pirenzepine can be increased when it is combined with Teduglutide.Approved
TheophyllineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Theophylline.Approved
TilidineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tilidine.Experimental
TiotropiumPirenzepine may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Pirenzepine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pirenzepine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Trimethaphan.Approved
TropatepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pirenzepine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pirenzepine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Pirenzepine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Vecuronium.Approved
Food Interactions
  • Take 30 minutes before breakfast and at bedtime.

References

Synthesis Reference
Not Available
General References
  1. Czepita D: [Fundamentals of modern treatment of myopia]. Ann Acad Med Stetin. 2005;51(2):5-9. [PubMed:16519089 ]
External Links
Human Metabolome Database
HMDB14808
KEGG Compound
C07508
PubChem Compound
4848
PubChem Substance
46509029
ChemSpider
4682
BindingDB
39341
ChEBI
8247
ChEMBL
CHEMBL9967
Therapeutic Targets Database
DAP000492
PharmGKB
PA10159
Wikipedia
Pirenzepine
ATC Codes
A02BX03 — Pirenzepine
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (36.5 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral50 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP0.6Not Available
Caco2 permeability-6.36ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.682 mg/mLALOGPS
logP1.26ALOGPS
logP0.85ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)9.57ChemAxon
pKa (Strongest Basic)7.59ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area68.78 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity100.93 m3·mol-1ChemAxon
Polarizability37.11 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9917
Blood Brain Barrier+0.9737
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8101
P-glycoprotein inhibitor IInhibitor0.5362
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.5983
CYP450 2C9 substrateNon-substrate0.7426
CYP450 2D6 substrateNon-substrate0.5571
CYP450 3A4 substrateSubstrate0.6503
CYP450 1A2 substrateInhibitor0.5788
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8814
CYP450 3A4 inhibitorNon-inhibitor0.8958
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.5
CarcinogenicityNon-carcinogens0.946
BiodegradationNot ready biodegradable0.9839
Rat acute toxicity1.8779 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6797
hERG inhibition (predictor II)Non-inhibitor0.5475
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Organoheterocyclic compounds
Sub Class
Benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Pyridodiazepines / Alpha amino acids and derivatives / N-piperazineacetamides / N-methylpiperazines / Benzenoids / Pyridines and derivatives / Imidolactams / Tertiary carboxylic acid amides / Cyclic carboximidic acids / Heteroaromatic compounds
show 7 more
Substituents
Pyrido-para-diazepine / 1,4-benzodiazepine / Alpha-amino acid or derivatives / N-piperazineacetamide / N-methylpiperazine / N-alkylpiperazine / 1,4-diazinane / Piperazine / Pyridine / Imidolactam
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyridobenzodiazepine (CHEBI:8247 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Pedretti RF, Prete G, Foreman RD, Adamson PB, Vanoli E: Autonomic modulation during acute myocardial ischemia by low-dose pirenzepine in conscious dogs with a healed myocardial infarction: a comparison with beta-adrenergic blockade. J Cardiovasc Pharmacol. 2003 May;41(5):671-7. [PubMed:12717096 ]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:42